Analysts Expect Cidara Therapeutics Inc (CDTX) to Announce -$0.54 EPS

Wall Street analysts expect Cidara Therapeutics Inc (NASDAQ:CDTX) to announce earnings of ($0.54) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Cidara Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.53) and the lowest estimate coming in at ($0.54). Cidara Therapeutics reported earnings per share of ($0.69) during the same quarter last year, which suggests a positive year over year growth rate of 21.7%. The company is scheduled to report its next earnings report on Tuesday, February 26th.

On average, analysts expect that Cidara Therapeutics will report full year earnings of ($2.86) per share for the current financial year, with EPS estimates ranging from ($3.16) to ($2.46). For the next fiscal year, analysts anticipate that the firm will report earnings of ($1.92) per share, with EPS estimates ranging from ($2.10) to ($1.62). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side analysts that follow Cidara Therapeutics.

Cidara Therapeutics (NASDAQ:CDTX) last issued its earnings results on Thursday, November 8th. The biotechnology company reported ($0.49) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.60) by $0.11.

Several brokerages recently weighed in on CDTX. Zacks Investment Research raised shares of Cidara Therapeutics from a “hold” rating to a “buy” rating and set a $3.25 target price on the stock in a report on Monday, January 14th. ValuEngine cut shares of Cidara Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, December 18th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $10.06.

Hedge funds have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. raised its holdings in Cidara Therapeutics by 88.5% during the third quarter. JPMorgan Chase & Co. now owns 149,050 shares of the biotechnology company’s stock worth $656,000 after purchasing an additional 69,998 shares in the last quarter. Bridgeway Capital Management Inc. raised its holdings in Cidara Therapeutics by 90.4% during the third quarter. Bridgeway Capital Management Inc. now owns 179,000 shares of the biotechnology company’s stock worth $788,000 after purchasing an additional 85,000 shares in the last quarter. Raymond James & Associates raised its holdings in Cidara Therapeutics by 104.1% during the second quarter. Raymond James & Associates now owns 195,878 shares of the biotechnology company’s stock worth $1,019,000 after purchasing an additional 99,927 shares in the last quarter. Renaissance Technologies LLC raised its holdings in Cidara Therapeutics by 8.6% during the third quarter. Renaissance Technologies LLC now owns 309,700 shares of the biotechnology company’s stock worth $1,363,000 after purchasing an additional 24,400 shares in the last quarter. Finally, Fosun International Ltd acquired a new stake in Cidara Therapeutics during the third quarter worth approximately $1,365,000. 65.20% of the stock is currently owned by institutional investors.

NASDAQ:CDTX traded up $0.01 during mid-day trading on Tuesday, hitting $2.95. The stock had a trading volume of 125,000 shares, compared to its average volume of 82,543. The stock has a market cap of $81.59 million, a price-to-earnings ratio of -0.93 and a beta of 2.13. Cidara Therapeutics has a twelve month low of $1.94 and a twelve month high of $8.55. The company has a quick ratio of 6.78, a current ratio of 6.78 and a debt-to-equity ratio of 0.13.

Cidara Therapeutics Company Profile

Cidara Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-infectives for the treatment of diseases. Its lead product candidate is rezafungin acetate, a molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, fungal infections associated with high mortality rates.

Recommended Story: Can individual investors take part in an IPO?

Get a free copy of the Zacks research report on Cidara Therapeutics (CDTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Cidara Therapeutics (NASDAQ:CDTX)

Receive News & Ratings for Cidara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cidara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit